1. |
Inhibition of complement C1s with sutimlimab in patients with cold agglutinin disease (CAD): 2 year follow up from the CARDINAL study (口頭発表,一般) 2023/06/09
|
2. |
Long term safety and efficacy of efgartigimod in patients with primary immune thrombocytopenia: interim results of the ADVANCE+ study (口頭発表,一般) 2023/06/08
|
3. |
Intravenous efgartigimod in adults with primary immune thrombocytopenia: results from the ADVANCE IV trial. (口頭発表,一般) 2023/04/25
|
4. |
SARS-Cov-2ワクチン接種後に発症した後天性血栓性血小板減少性紫斑病 (口頭発表,一般) 2023/03/11
|
5. |
後天性血友病A患者の出血リスクが高い経皮腎瘻造設術に対するエミシズマブとrFVIIaによる周術期管理 (口頭発表,一般) 2023/03/11
|
6. |
Efficacy and safety of intravenous Efgartigimod in adults with primary immune thrombocytopenia: results of ADVANCE IV, a Phase 3, multicentr, double-blinded, placebo-controlled, randomized clinical trial (口頭発表,一般) 2022/12/11
|
7. |
HELLP症候群との鑑別を要する妊娠関連TMA (口頭発表) 2022/10/29
|
8. |
Two-Year Efficacy and Safety of Ravulizumab in Adults and Children with Atypical Hemolytic Uremic Syndrome: Analysis of Two Phase 3 Studies (ポスター,一般) 2022/10/17
|
9. |
後天性血栓性血小板減少性紫斑病(TTP)診断と新規治療:抗VWF抗体カプラシズマブ (口頭発表) 2022/10/16
|
10. |
Efficacy and safety of caplacizumab for thrombotic thrombocytopenic purpura: Japanese Phase 2/3 study (口頭発表,一般) 2022/10/15
|
11. |
Phamacokinetic and pharmacodynamic simulations guide selection of the dose for administration of efgartigimod PH20 subcutaneously in a Phase 3 clinical trial in patients with primary immune thrombocytopenia (口頭発表,一般) 2022/09/26
|
12. |
Inhibition of complement C1s with sutimlimab in patients with cold agglutinin disease (CAD): a 2 year follow up from the CARDINAL study (口頭発表,一般) 2022/06/10
|
13. |
Inhibition of complement C1s with sutimlimab in patients with cold agglutinin diseasse (CAD): 2 year follow up from the CADRINAL study (口頭発表,一般) 2022/06/10
|
14. |
Inhibition of complement C1s with sutimlimab in patients with cold agglutinin disease, 2 year follow up from the CARDINAL study (ポスター,一般) 2022/06/09
|
15. |
Inhibition of complement C1s with sutimlimab in patients with cold aggulutinin disease , results following 9 week wash out period in phase 3 cardinal study. (ポスター,一般) 2022/06/09
|
16. |
Sutimlimab, a complement C1s inhibitor, provides sustained improvements in patient-reported outcomes in patients with cold agglutinin disease, 2 year follow up from the CARDINAL study (ポスター,一般) 2022/06/09
|
17. |
Eculizumab for adult patients with atypical haemolytic uremic syndrome: full dataset analysis of post-marketing surveillance in Japan (口頭発表,一般) 2022/05/20
|
18. |
La modélisation pharmacocinétique-pharmacodynamique supporte la sélection de la dose d'efgartigimod à administrer par voie sous-cutanée dans un essai clinique de phase 3 chez des patients atteints de purpura thrombopénique immunologique (ポスター,一般) 2021/12/16
|
19. |
Two year efficacy and safety of ravulizumab in adults and children with atypical HUS: analysis of two phase 3 studies. (口頭発表,一般) 2021/12/06
|
20. |
Phamakokinetic and pharmakodynamic simulations guide selection of the dose for administration of Efgartigimod PH20 subctutaneously in a phase 3 clinical trial in patients with primary immune thrombocytopenia (口頭発表,一般) 2021/12/05
|
5件表示
|
全件表示(20件)
|